Skip to main navigation Skip to search Skip to main content

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallelgroup, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease

Project: Research

Project Details

StatusActive
Effective start/end date02/19/25 → 05/1/27

Funding

  • AstraZeneca Pharmaceuticals LP: $34,061.18